期刊
BRITISH JOURNAL OF PSYCHIATRY
卷 211, 期 1, 页码 7-+出版社
CAMBRIDGE UNIV PRESS
DOI: 10.1192/bjp.bp.116.195776
关键词
-
类别
资金
- Tianjin Health Bureau [2014KR02]
- Chinese Postdoctoral Science Foundation [2012M0585]
- Jiangsu Haosen pharmaceutical Limited by Share Ltd
- Hainan Liou pharmaceutical Limited by Share Ltd
- Xuzhou Enhua pharmaceutical Limited by Share Ltd
- Shanghai Zhongxi pharmaceutical Limited by Share Ltd
Background Previous studies have reported conflicting results on the association between schizophrenia and cancer mortality. Aims To summarise available evidence and quantify the association between schizophrenia and cancer mortality using meta-analysis. Method We systematically searched literature in the PubMed and Embase databases. Risk estimates and 95% confidence intervals reported in individual studies were pooled using the DerSimonian-Laird random-effects model. Results We included 19 studies in the meta-analysis. Among them, 15 studies reported standardised mortality ratios (SMRs) comparing patients with schizophrenia with the general population, and the pooled SMR was 1.40 (95% Cl 1.29-1.52, P < 0.001). The other four studies reported hazard ratios (HRs) comparing individuals with schizophrenia with those without schizophrenia; the pooled HR was 1.51 (95% Cl 1.13-2.03, P = 0.006). Conclusions Patients with schizophrenia are at a significantly increased risk of cancer mortality compared with the general population or individuals without schizophrenia.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据